For Providers
The Endocrine Activity Index (EAI) gives healthcare providers a new innovative tool with actionable results to inform & refine breast cancer treatment decisions for your patients.
Optimize Treatment Decision Making
For breast oncologists, today’s diagnostic tests answer broad questions to inform breast cancer treatment decisions. With the addition of the Endocrine Activity Index into your practice, you will gain more information about your patients’ long-term outcomes as well as understand which patients may benefit most from dose-intense paclitaxel-based chemotherapy.
Technology & Sample Process Overview
The testing and sample process for the Endocrine Activity Index is a multi-step process from ordering to resulting.
Ordering & Collection
A test order is completed and sample of tumor tissue is collected
Sample Preparation
The tissue is prepared for analysis
Sample Submission
The sample is shipped to the laboratory
Laboratory Analysis
The laboratory performs genomic analysis
Results Available
The analysis yields index score and recurrence risk results
Endocrine Activity Index
The Endocrine Activity Index is predictive of dose-intense paclitaxel-based chemotherapy benefit. EAI measures endocrine transcriptional activity in Stage II-III, HR+, HER2- breast cancer patients. Patients with low levels of endocrine activity, determined by the EAI, demonstrated improved survival when treated with dose-intense paclitaxel-based chemotherapy for both pre- and post-menopausal patients.
Endocrine Activity Index RR
The Endocrine Activity Index Recurrence Risk (EAI RR) has been shown to be a consistent prognostic indicator for long-term outcomes in Stage II-III breast cancer patients. EAI RR combines the genomic measurement of endocrine activity with baseline tumor and patient risk factors to inform breast cancer prognosis.
Metzger O, et al. Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13). 2024 American Society of Clinical Oncology Annual Meeting, Chicago, IL. May 31-Jun 4, 2024. J Clin Oncol 42, 2024 (suppl 16; abstr 538), DOI: 10.1200/JCO.2024.42.16_suppl.538
Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 Jan 17:JCO2201499. doi: 10.1200/JCO.22.01499. Epub ahead of print. PMID: 36649570.